Bolt Biotherapeutics Q3 2021: cash $290.5M; BDC-1001 interim data at ESMO I-O in Dec

Bolt Biotherapeutics, Inc.

2022-Q3 EPS reported -$2.24 revenue$752,000

Cash, cash equivalents and marketable securities $290.5M at Sep 30, 2021; plus $5M upfront from Innovent in Oct.
Operating loss $23.5M in Q3 2021 vs $12.4M in Q3 2020; R&D expenses rose to $19.3M.
BDC-1001 Phase 1/2 monotherapy interim data (>50 patients) to be presented at ESMO I-O Congress in Dec 2021.
Combination dose escalation with Opdivo expected to start Q4 2021; collaboration with Innovent for up to 3 ISACs.
Cash expected to fund operations through end of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.